Below are the chemical structures of Merck's molnupiravir (left) and
Three monoclonal antibodies (MABs) such as cocktail of casirivimab–imdevimab (REGEN-COV™), and bamlanivimab–etesevimab, and single
Merck & Co Inc
In this work, we compare efficacy of molnupiravir and nirmatrelvir/ritonavir in the Roborovski dwarf hamster model of severe COVID-19-like viral pneumonia and the
Molnupiravir is the oral prodrug of beta-D-N4-hydroxycytidine (NHC), a ribonucleoside that has shown antiviral activity against SARS-CoV-2 in vitro and in some
Regarding the hospitalization rate, two studies reported the hospitalization rate in the current meta-analysis and demonstrated that molnupiravir was associated